ArticleJournal of cachexia, sarcopenia and muscle2023
Analysis of the adiponectin paradox in healthy older people.
Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Circulating METRNL, Adipocytokines, and Insulin-Resistance Markers After Repeated Whole-Body Cryotherapy in Women of Different Ages.International journal of molecular sciences · 2026Article
- Assessment of Cardiovascular Risk in Long-Term Type 1 Diabetes: The Role of Adiponectin and Leptin.Medicina (Kaunas, Lithuania) · 2026Article
- Proteomics of aging: biomarkers for physiological systems and diseases.Frontiers in aging · 2026Review
- Malnutrition-Sarcopenia Syndrome in older adults: Causes, consequences, and countermeasures.EXCLI journal · 2026Review
- Disuse-induced muscle-type specific alterations and adiponectin pathway response in male mice.Physiological reports · 2025Article
- Effects of Outdoor and Household Air Pollution on Hand Grip Strength in a Longitudinal Study of Rural Beijing Adults.International journal of environmental research and public health · 2025Article
- Exerkines and myokines in aging sarcopenia.Frontiers in endocrinology · 2025Review
- Osteosarcopenia in metabolic dysfunction-associated steatotic liver disease: from mechanisms to management.Frontiers in endocrinology · 2025Review
- Association of biomarkers and Barthel Index with occurrence of age-related adverse health outcomes in individuals with diabetes.Journal of diabetes investigation · 2024Article
- Reevaluating Adiponectin's impact on obesity hypertension: a Chinese case-control study.BMC cardiovascular disorders · 2024Article
- Preliminary Report on the Influence of Acute Inflammation on Adiponectin Levels in Older Inpatients with Different Nutritional Status.International journal of molecular sciences · 2024Article
- Limitations in metabolic plasticity after traumatic injury are only moderately exacerbated by physical activity restriction.npj metabolic health and disease · 2024Article
- Sarcopenia, a condition shared by various diseases: can we alleviate or delay the progression?Internal and emergency medicine · 2023Review
- Determinants of bone mass in older adults with normal- and overweight derived from the crosstalk with muscle and adipose tissue.Scientific reports · 2023Article
- Analysis of the adiponectin paradox in healthy older people.Journal of cachexia, sarcopenia and muscle · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundIt remains unknown why adiponectin levels are associated with poor physical functioning, skeletal muscle mass and increased mortality in older populations.
methodsIn 190 healthy adults (59-86 years, BMI 17-37 kg/m
resultsHigher adiponectin levels were associated with a lower SMI (r = -0.23, P < 0.01), BMC (r = -0.17, P < 0.05) and liver fat (r = -0.20, P < 0.05) in the total population and with higher muscle fat in women (r = 0.27, P < 0.01). By contrast, IGF-1 showed positive correlations with SMI (r = 0.33), BMD (r = 0.37) and BMC (r = 0.33) (all P < 0.01) and a negative correlation with muscle fat (r = -0.17, P < 0.05). IGF-1 was negatively associated with age (r = -0.21, P < 0.01) and with adiponectin (r = -0.15, P < 0.05). Stepwise regression analyses revealed that IGF-1, insulin and leptin explained 18% of the variance in SMI, and IGF-1, leptin and age explained 16% of the variance in BMC, whereas adiponectin did not contribute to these models.
conclusionsAssociations between higher adiponectin levels and lower muscle or bone mass in healthy older adults may be explained by a decrease in IGF-1 with increasing adiponectin levels.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.